SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp is trending due to significant institutional interest surrounding its pivot toward AI-focused power infrastructure and the anticipation of upcoming hyperscaler lease announcements. The community is actively discussing the stock's potential for a valuation re-rating, with traders highlighting recent technical momentum and the firm's strategic positioning ahead of index fund inflows.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following strong 52-week VELA trial results that demonstrate clinical superiority and durability, fueling community speculation about a potential buyout. Investors are actively discussing the company's best-in-class profile and upcoming regulatory milestones, with many viewing the asset as a prime candidate for acquisition by a major pharmaceutical firm.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending following positive topline Phase 3 Emerge study results, which showed statistically significant and clinically meaningful improvement in major depressive disorder. Community discussion remains highly focused on the upcoming readouts for the company's GAD programs, with investors debating the stock's potential for a broader re-rate while weighing the ongoing risks of cash burn and future dilution.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending as investors rally around a significant $2 billion convertible senior notes offering, with the community highly focused on the company's strategic use of proceeds for share repurchases and aggressive global expansion. Traders are closely monitoring the stock's reclaim of key technical moving averages, fueling intense debate between long-term bulls betting on ecosystem growth and day traders navigating sharp intraday volatility.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending as a primary beneficiary of the AI-driven memory supercycle, with the community actively debating whether its parabolic rise represents sustainable structural growth or a speculative bubble reminiscent of the dot-com era. Traders remain sharply divided between aggressive bulls targeting further highs and skeptics calling for a correction, while attention shifts toward upcoming earnings catalysts in the broader semiconductor sector.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is in the spotlight following the FDA's decision to issue a Complete Response Letter (CRL) for its Hunter syndrome gene therapy, NAVSUNLI, effectively rejecting the current application while demanding additional data. Investors are now shifting their focus toward the company's long-term pipeline potential, specifically the RGX-202 program for Duchenne muscular dystrophy and the ongoing wet AMD collaboration with AbbVie, as the community debates whether current valuations adequately reflect the company's remaining cash runway and development milestones.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda to advance solid-state battery development and manufacturing processes. The community is actively discussing whether this partnership marks a major milestone for the companys commercial viability, with many investors debating the long-term potential for expansion into broader sectors like robotics and AI data centers.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant momentum as investors digest a positive analyst upgrade and anticipation builds for next month's FDA peptide review. The stock's recent breakout above key moving averages has the community actively debating whether this is the start of a sustained valuation re-rating or another cycle of volatility driven by heavy short interest.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors digest the fallout from shifting U.S.-China trade dynamics and internal insider selling, while simultaneously betting on the long-term strategic importance of the company's domestic mine-to-magnet infrastructure. Community sentiment remains polarized, with many market participants viewing the recent volatility as a prime accumulation opportunity for a key national security asset, while others remain focused on technical resistance levels and executive trading activity.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a strategic partnership with Midjourney to integrate its ultrasound-on-chip technology into new AI-powered diagnostic hardware. While the community is debating whether this deal signals a long-term growth catalyst or an overhyped sell-the-news event, the stock is seeing heightened volatility and significant volume as market participants weigh the company's persistent cash burn against its potential to scale through these embedded technology licensing agreements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Key Points814,606 common shares acquired for a total transaction value of approximately $12.5 million, based on a weighted average price of $15.29 per share...

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year.

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS in the treatment of lupus nephritis is being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress (EULAR 2026 Presentation). This new...

Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy

AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

Equity

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Inc. Profit Advances In Q1

(RTTNews) - Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for its first quarter that Increased, from last year...

Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +20.83% and +2.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 9,112,230 shares, a decrease of 15.7% from the March 31st total of 10,809,496 shares...

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are actively debating potential takeover scenarios and buyout catalysts amid high revenue metrics and debt-free financials.

Traders are closely watching significant share blocks, liquidity gaps, and key technical resistance levels around $16.50.

Discussions center on recent executive purchasing patterns and changes in C-suite leadership driving market confidence.

AUPHAurinia Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUPH News